Cost-Effectiveness of a Novel Treatment for Stroke Prevention in Patients with Atrial Fibrillation: Results from an Early Economic Analysis

Author(s)

Benner J1, Bloomfield D2, Mehta N2, Yi BA2
1Stratevi, Boston, MA, USA, 2Anthos Therapeutics, Cambridge, MA, USA

OBJECTIVES: For many patients with atrial fibrillation (AF) at moderate-to-high risk of stroke, clinically significant bleeding from anticoagulants remains a concern, leading to withholding or discontinuation of anticoagulation. Patients who are unsuitable for or inadequately treated with currently available anticoagulants remain at higher risk for stroke and systemic embolism. This early economic analysis explored the potential cost-effectiveness of a hypothetical new therapy that reduces the risk of stroke in patients with AF who are unsuitable for treatment with currently available anticoagulants.

METHODS: Following NICE guidance, a Markov model was developed to reflect the clinical pathways typical of patients with AF at moderate-to-high risk of stroke who are unsuitable for treatment with currently available anticoagulants. Use of a hypothetical new treatment was compared with usual care from a UK perspective. A plausible range of stroke risk for the new treatment was assessed. Total costs and quality-adjusted life years over a lifetime were compared.

RESULTS: Compared to usual care, a new treatment that reduced the risk of stroke by at least 9% was cost-effective at a £30k/QALY threshold assuming a monthly cost that is 20% higher than apixaban, a commonly prescribed anticoagulant, and relative risks of 0.75, 1.3, and 1.0 for myocardial infarction, bleeds, and intracranial hemorrhage versus usual care. Considering a range between 0.5-0.8 for the relative risk of stroke versus usual care, the new treatment remained cost-effective up to a price 2.8-14 times higher than apixaban.

CONCLUSIONS: A new treatment option for patients with AF at moderate-to-high risk of stroke who are unsuitable for treatment with currently available anticoagulants is a potentially cost-effective treatment option.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

EE344

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Drugs

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×